Biogen Inc
NASDAQ: BIIB
$159.99
-$4.90 (-3.0%)
Closing Price on November 15, 2024
BIIB Articles
The March 31 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Published:
Last Updated:
Despite a modest erosion to fundamentals and sector headwinds, Jefferies does not anticipate any dramatic earnings misses, which could help sentiment continue to turn around.
Published:
Last Updated:
The February 29 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Published:
Last Updated:
Citigroup came out with a biotech upgrade of sorts on Thursday. The firm issued brand new Buy ratings on four of the largest names within the biotech space.
Published:
Last Updated:
The February 12 short interest data have been compared with the previous report, and short interest increased across the board in these selected biotech stocks.
Published:
Last Updated:
The January 29 short interest data have been compared with the previous report, and short interest was mixed in most of the selected biotech stocks.
Published:
Last Updated:
A recent Jefferies research note indicates that the multiples for the four largest biotechs have dipped below that of the S&P for the first time since early in 2011, despite displaying higher...
Published:
Last Updated:
Jefferies has four top biotech picks for 2016 that all have substantial upside and may provide investors with solid alpha for 2016.
Published:
Last Updated:
Short interest increased in most of these selected biotech stocks for the most recent settlement date.
Published:
Last Updated:
Biogen reported better-than-expected fourth-quarter financial results before the markets opened on Wednesday.
Published:
Last Updated:
Biogen is set to report its fourth-quarter financial results before the markets open Wednesday.
Published:
Last Updated:
These companies are well along in clinical trials and some are close to presenting Phase 3 results. Sticking with industry leaders always makes sense in a very volatile sector.
Published:
Last Updated:
The short interest data are out for the December 31 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
Published:
Last Updated:
The top analyst calls for Wednesday, January 6, 2016, include Bluebird Bio, Check Point Software, Comcast, Eli Lilly, Hyatt Hotels, Lockheed Martin and Rite Aid.
Published:
Last Updated:
The short interest data are out for the December 15 settlement date, and short interest continued to be mixed in these selected biotech stocks.
Published:
Last Updated: